We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 87.860.0%Oct 23 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Longtimeinvestor who wrote (52178)8/21/2019 6:04:31 PM
From: idahoranch12 Recommendations

Recommended By

   of 59398
I think the last two days are likely the CRL SRPT got from FDA. It was unexpected and at least to me, the reasons seem confusing. There is less confidence in FDA acting rationally by investors than two days ago.

Of course I’ve been on the “not trusting” side for a while now. Logically, our approval should be based on the companies manufacturing facility inspection which I expect has been brought up to and exceeding all that FDA has asked.

The question is, like us the first time around, and SRPT yesterday, is FDA withholding communications on important items from the company that they will then use to issue a CRL? I really don’t think so, but the selling suggests there’s more of a concern since SRPT’s CRL than there was before.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext